Rhythm eyes a pivotal test after rolling through PhII with upbeat results for rare obesity cases
Boston-based Rhythm can now boast about publishing the results of a new Phase II obesity drug study in the prestigious New England Journal of Medicine. The data, while only covering two patients, points to the potential of their drug setmelanotide for extremely rare cases of pro-opiomelanocortin (POMC) deficiency. And the biotech is moving to a mid-stage readout for another program on Prader-Willi syndrome, which just defeated Zafgen’s pivotal efforts after two patients died in their study, as it sets the stage for a near-term pivotal trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.